A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

NCT06271252 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Multiple Myeloma

Interventions

DRUG: OriCAR-017

Sponsor

OriCell Therapeutics Co., Ltd.